Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent

Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent

US Patent 8828392 · Granted Sep 9, 2014

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Rapamycin for the treatment of lymphangioleiomyomatosis2024
Methods and apparatus for making biological predictions using a trained multi-mo2024
Combination therapy with apilimod and glutamatergic agents2024
Building panel assembly and method of manufacturing2024
Rapamycin for the treatment of lymphangioleiomyomatosis2023
Inhalable rapamycin formulation for treating age-related conditions2023
Inhalable rapamycin formulation for the treatment of pulmonary hypertension2022
Combination therapy with apilimod and glutamatergic agents2022
Cryptography system and method2022
Apilimod compositions and methods for using same2022
Apilimod compositions and methods for using same in the treatment of renal cance2021
Rapamycin for the treatment of lymphangioleiomyomatosis2021